Small molecule modulation of TrkB and TrkC neurotrophin receptors prevents cholinergic neuron atrophy in an Alzheimer's disease mouse model at an advanced pathological stage.

Autor: Gonzalez S; Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305, United States of America., McHugh TLM; Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305, United States of America., Yang T; Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305, United States of America., Syriani W; Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305, United States of America., Massa SM; Department of Neurology, Laboratory for Computational Neurochemistry and Drug Discovery, Veterans Affairs Health Care System and Department of Neurology, University of California-San Francisco, San Francisco, CA 94121, United States of America., Longo FM; Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305, United States of America., Simmons DA; Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305, United States of America. Electronic address: simmons3@stanford.edu.
Jazyk: angličtina
Zdroj: Neurobiology of disease [Neurobiol Dis] 2022 Jan; Vol. 162, pp. 105563. Date of Electronic Publication: 2021 Nov 24.
DOI: 10.1016/j.nbd.2021.105563
Abstrakt: Degeneration of basal forebrain cholinergic neurons (BFCNs) in the nucleus basalis of Meynert (NBM) and vertical diagonal band (VDB) along with their connections is a key pathological event leading to memory impairment in Alzheimer's disease (AD). Aberrant neurotrophin signaling via Trks and the p75 neurotrophin receptor (p75 NTR ) contributes importantly to BFCN dystrophy. While NGF/TrkA signaling has received the most attention in this regard, TrkB and TrkC signaling also provide trophic support to BFCNs and these receptors may be well located to preserve BFCN connectivity. We previously identified a small molecule TrkB/TrkC ligand, LM22B-10, that promotes cell survival and neurite outgrowth in vitro and activates TrkB/TrkC signaling in the hippocampus of aged mice when given intranasally, but shows poor oral bioavailability. An LM22B-10 derivative, PTX-BD10-2, with improved oral bioavailability has been developed and this study examined its effects on BFCN atrophy in the hAPP Lond/Swe (APP L/S ) AD mouse model. Oral delivery of PTX-BD10-2 was started after appreciable amyloid and cholinergic pathology was present to parallel the clinical context, as most AD patients start treatment at advanced pathological stages. PTX-BD10-2 restored cholinergic neurite integrity in the NBM and VDB, and reduced NBM neuronal atrophy in symptomatic APP L/S mice. Dystrophy of cholinergic neurites in BF target regions, including the cortex, hippocampus, and amygdala, was also reduced with treatment. Finally, PTX-BD10-2 reduced NBM tau pathology and improved the survival of cholinergic neurons derived from human induced pluripotent stem cells (iPSCs) after amyloid-β exposure. These data provide evidence that targeting TrkB and TrkC signaling with PTX-BD10-2 may be an effective disease-modifying strategy for combating cholinergic dysfunction in AD. The potential for clinical translation is further supported by the compound's reduction of AD-related degenerative processes that have progressed beyond early stages and its neuroprotective effects in human iPSC-derived cholinergic neurons.
(Copyright © 2021. Published by Elsevier Inc.)
Databáze: MEDLINE
Externí odkaz: